cotyledoside: glycoside isolated from Tylecodon wallichii; structure in first source
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Tylecodon | genus | A plant genus. Members contain BUFANOLIDES.[MeSH] | Crassulaceae | The stonecrop plant family of the order ROSALES, subclass Rosidae, class Magnoliopsida that grow in warm, dry regions. The leaves are thick. The flower clusters are red, yellow, or white.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 162820 |
MeSH ID | M0115440 |
Synonym |
---|
cotyledoside |
57364-74-6 |
bufa-20,22-dienolide, 7,8-epoxy-14-hydroxy-2,3-((tetrahydro-3,5-dihydroxy-4-methoxy-6-methyl-2h-pyran-4,2-diyl)bis(oxy))-, (2alpha(2s,3r,4s,5r,6s),3beta,5alpha,7beta)- |
DTXSID20972871 |
5-(3a,11,17-trihydroxy-12-methoxy-10,14a,16a-trimethyloctadecahydro-8h,10h-8,12-methanocyclopenta[7,8]oxireno[8a,9]phenanthro[2,3-d][1,3,6]trioxonin-1-yl)-2h-pyran-2-one |
5-(13,25,26-trihydroxy-1-methoxy-5,9,24-trimethyl-2,15,21,23-tetraoxaheptacyclo[20.3.1.03,20.05,18.06,14.09,13.014,16]hexacosan-10-yl)pyran-2-one |
Excerpt | Relevance | Reference |
---|---|---|
" When dosed subcutaneously, a cumulative effect was observed." | ( Studies on South African cardiac glycosides. II. Observations on the clinical and haemodynamic effects of cotyledoside. Naudé, TW; Schultz, RA, 1982) | 0.48 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (28.57) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.68) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |